Caduet enhances connexin 43 phosphorylation in left ventricular and thoracic aorta of SH model rats
- Authors:
- Published online on: September 11, 2020 https://doi.org/10.3892/etm.2020.9207
- Article Number: 80
-
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Abstract
Introduction
Spontaneous hypertension (SH) is one of the most critical factors in leading to cardiovascular diseases (1,2). Persistently elevated blood pressure in patients who are hypertensive results in vascular tone increasement and vascular smooth muscle systolic dysfunction, leading to myocardial ischemia and ventricular and vascular remodeling (3,4). Furthermore, left ventricular and aorta remodeling is a frequent pathological change in hypertension, which contributes to arrhythmia, heart failure and cardiovascular mortality (5-7).
Caduet is a single pill containing a combination of amlodipine besylate and atorvastatin calcium tablet (AM + AT), which is widely used in the clinical treatment of cardiovascular diseases, such as hypertension and coronary heart disease (8). In addition, previous experimental and clinical studies have reported that AM + AT can prevent cardiac hypertrophy and remodeling (9,10).
The gap junction (GJ) channel is the structural basis for cellular electric coupling and signal transmission, which mainly functions though regulating the GJ protein connexin (11,12). Connexin 43 (Cx43)-associated GJ protein in ventricular cardiomyocytes and vascular smooth muscle cells is involved in cardiac and vascular remodeling (13). Moreover, left ventricular remodeling is closely associated with the expression and distribution of Cx43 in cardiomyocytes (9,14), and our previous study revealed that the expression of Cx43 was enhanced in the thoracic aorta of SH model rats (SHR) (15). Previous studies have also reported that Cx43 phosphorylation contributes to ischemia-associated remodeling of Cx43 channels in cardiomyocytes (16,17), and Cx43 dephosphorylation contributes to arrhythmias and cardiomyocyte apoptosis in ischemia/reperfusion hearts (18). Based on these clinical data and laboratory reports, it was hypothesized that Cx43 phosphorylation may be involved in the process of hypertensive left ventricular and thoracic aorta remodeling, and AM + AT may improve this remodeling by enhancing Cx43 phosphorylation.
Therefore, the aim of the present study was to investigate the effect of Cx43 phosphorylation in the process of hypertensive left ventricular and thoracic aorta remodeling, and to examine whether AM + AT improved this remodeling by regulating Cx43 phosphorylation.
Materials and methods
Experimental reagents
A ProteoPrep Total Extraction Sample kit was obtained from Sigma-Aldrich (Merck KGaA), the BCA protein assay kit was from Beyotime Institute of Biotechnology and nitrocellulose membrane was purchased from Thermo Fisher Scientific, Inc. Primary antibody against rat total (T)-Cx43 was obtained from Thermo Fisher Scientific, Inc. (1:1,000 for western blotting; 1:100 for immunofluorescence; cat. no. 3D8A5). Primary antibody against rat phosphorylated (P)-Cx43 was obtained from Cell Signaling Technology (1:1,000 for western blotting; 1:100 for immunofluorescence; cat. no. 52559). Horseradish peroxidase (HRP)-conjugated goat anti-mouse (1:1,000; cat. no. G-21040) and goat anti-rabbit polyclonal (1:1,000; cat. no. 31466) secondary antibodies were obtained from Thermo Fisher Scientific, Inc. ECL reagents were purchased from Thermo Fisher Scientific, Inc. (cat. no. 35055). The FITC-conjugated goat anti-mouse secondary antibody was obtained from Thermo Fisher Scientific, Inc. (1:50; cat. no. 62-6511), and the tetramethylrhodamine isothiocyanate (TRITC)-conjugated goat anti-rabbit secondary antibody was purchased from Thermo Fisher Scientific, Inc. (1:100; cat. no. A16101). Bovine serum albumin (BSA) was from Thermo Fisher Scientific, Inc. (cat. no. 37520).
Drugs and animals
The Chinese drug administration license nos. of AM, AT and AM + AT were H10950224, J20070061 and J20171045, respectively, which were from Betriebsstätte Freiburg, Inc.. All procedures and ethics associated with animal use were reviewed and approved by Medical School of Xi'an Jiaotong University (approval no. 2018-898). In total, 32 male SHR (age, 8 weeks; weight, 210-265 g) were obtained from Weitong Lihua Experimental Animal Technology Co., Ltd, with clean grade certificate [SCXK (Beijing) 2007-0001], and eight Wistar-Kyoto (WKY) rats were purchased from Skerries Laboratory Animal Center, Ltd. as the WKY control group, with clean grade certificate [SCXK (Shanghai) 2007-0005]. The AM group (SHR-AM; n=8), AT group (SHR-AT; n=8) and AM + AT group (SHR-AM + AT; n=8) were orally administered 10 mg/kg/day of AM, AT or AM + AT as treatment groups for 8 weeks (19,20), respectively. The WKY control group (n=8) and SHR control group (n=8) were orally administrated with the same volume of water as the treatment group. All rats received humane care and were raised in the same clean environment, with ambient temperature at 22±1˚C, humidity of 50±5%, 14/10-h light/dark cycle, free access to food and water.
Measurement of body weight, heart rate (HR), left ventricular mass index (LVMI), blood pressure and plasma lipid levels in each group
The systolic blood pressure (SBP) and diastolic blood pressure (DBP) of the rats were measured at 0, 2, 4, 6 and 8 weeks after treatment using the Non-Invasive Blood Pressure system (LE-5001 HX-II tail-cuff small animal blood pressure meter; Panlab S.L.U). After 8 weeks, HR was measured and anal temperature were measured by thermometer. Then the rats were weighed and anesthetized with pentobarbital (40 mg/kg) via intraperitoneal injection. A total of 2 ml blood was collected from heart of every rat, and the plasma lipid levels of each group were measured using a Hitachi 7170 biochemical analyzer (Hitachi, Inc.); these included total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL) and triglycerides (TG). Then the chest of the rat was opened, the heart was quickly removed and the left ventricular free wall was cut along the atrioventricular ring and weighed as the LVMI (left ventricular mass/body weight; mg/g).
Comparison of pathological changes in cardiac tissues
The free wall of the left ventricle was fixed in 10% formaldehyde for 2 h at room, dehydrated in an ethanol gradient (80, 90, 95 and 100%), then embedded in paraffin. Sections (3 µm thick) were cut and conventionally dewaxed to water in a series, including xylene I, xylene II, 100% alcohol I and 100% alcohol II (10 min each), then a 95, 90, 80, 70% ethanol series (10 min each) and finally distilled water. Sections were stained with hematoxylin for 1 min, rinsed with water once, stained with eosin for 2 min, then dehydrated with conventional gradient alcohol (70, 80, 90 and 95% ethanol, 2 min each; 100% ethanol I, 100% alcohol II, 10 min each), cleared with xylene, and finally mounted with neutral gum and observed with Olympus BX41 fluorescent microscope (magnification, x400; Olympus Corporation). Images were captures and used to quantitatively analyze the myocardial cell cross-sectional area using Image-Pro Plus analysis software 6.0 (Media Cybernetics, Inc.).
Analysis of T-Cx43 and P-Cx43 protein expression levels in the left ventricular and thoracic aortic tissue using western blotting
Western blotting was performed as reported previously (21). Proteins of the left ventricular free wall and thoracic aortic ascending tissue were extracted using ProteoPrep Total Extraction Sample kit and measured using a BCA protein assay kit. Each sample was mixed with 40 µl 1X SDS electrophoresis sample buffer and boiled for 2-3 min. Protein samples (30 µg) were separated by 12% SDS-PAGE gel and transferred onto a nitrocellulose membrane. The membranes were blocked with 5% skimmed milk for 2 h at room temperature, and washed twice with Tris-buffered saline with 0.1% Tween-20. Membranes were incubated with T-Cx43 and P-Cx43 primary antibodies overnight at 4˚C, then probed with HRP-conjugated secondary antibody for 2 h at room temperature. Protein bands were visualized using ECL reagents and imaged using an Alpha Innotech FluorChem FC2 Imaging System (Alpha Innotech Inc.), the densitometric analysis was used ImageJ software v1.46 (National Institutes of Health), and β-actin expression was used to normalize the data.
Expression and distribution of T-Cx43 and P-Cx43 in the left ventricular and thoracic aortic tissue using immunofluorescence double labeling
The frozen tissue embedded with optimum cutting temperature compound was cut into 8-µm thick tissue sections and fixed for 15 min with pre-cooled acetone at 4˚C. Then, the samples were blocked with 1% BSA for 2 h at room temperature, and incubated with the primary antibodies against rat T-Cx43 and P-Cx43 at 4˚C overnight, followed by incubation with the FITC-conjugated secondary antibody at 37˚C for 1 h. Then, the sections were incubated with a TRITC-conjugated secondary antibody in 1% fetal bovine serum at 37˚C for 1 h in the dark. After washing three times with PBS (5 min each), five random fields of each section were examined under an Olympus BX41 fluorescent microscope (magnification, x400; Olympus Corporation), and the fluorescence intensity was determined using ImageJ software.
Statistical analysis
The data were analyzed with SPSS 21.0 statistical software (IBM Corp.). Data are presented as the mean ± SD; the experiments were repeated three times. Comparisons between groups were performed using one-way ANOVA followed Tukey's test. P<0.05 was considered to indicate a statistically significant difference.
Results
Comparison of body weight, HR and LVMI in each group
As presented in Table I, no significant differences were identified in the body weight in all groups after 8 weeks of drug treatment (P>0.05). It was demonstrated that HR and LVMI were significantly lower in treatment groups compared with the respective SHR group (P<0.05); and LVMI was especially lower in the SHR-AM + AT group.
Comparison of blood pressure, plasma lipid level and myocardial tissue morphology
After treatment for 8 weeks, SBP and DBP in the SHR-AM and SHR-AM + AT groups were significantly decreased compared with the SHR group (P<0.05; Fig. 1A). However, there was no difference between SHR-AM and SHR-AM + AT group (P>0.05; Fig. 1A).
The plasma lipid results identified that TC, LDL and TG in the SHR-AT + AM group were significantly lower compared with the SHR group (P<0.05), and TC and LDL was lower in the SHR-AM + AT compared with levels in the SHR-AM group (P<0.05; Fig. 1B). Furthermore, there was no significant difference in HDL in all groups (P>0.05).
Compared with the WKY group, hematoxylin and eosin staining demonstrated that the myocardiocytes in the SHR group were hypertrophied, swelled and arranged disorderly, and the cross-sectional area of cardiomyocytes were significantly increased (Fig. 1C). Furthermore, compared with SHR group, the cardiomyocyte was arranged regularly and the cross-sectional area was reduced in the treatment groups (P<0.05), with an enhanced reduction in the SHR-AM + AT group (P<0.05; Fig. 1D).
Comparison of T-Cx43 and P-Cx43 protein expression levels in the left ventricular and thoracic aortic tissue using western blotting in each group
Compared with the WKY group, the expression of T-Cx43 in the free wall of the left ventricle was significantly increased in the SHR group (P<0.05). After treatment, compared with the SHR group, the expression of T-Cx43 was significantly decreased in SHR-AM and SHR-AM+AT (P<0.05), especially in SHR-AM + AT group (Fig. 2A and B). Moreover, compared with the SHR group, the expression of P-Cx43 was significantly increased in treatment groups (Fig. 2A and C). And the P-Cx43/T-Cx43 ratio demonstrated significantly increased in treatment groups compared with the ratio in the SHR group, (P<0.05), especially in SHR-AM+AT (Fig. 2A and D). The results suggested that drug treatment could enhance P-Cx43 protein expression, and that AM + AT was superior to either AM or AT alone.
In thoracic aortic tissue, the expression of T-Cx43 was decreased in the treatment groups compared with the SHR group (P<0.05), especially in SHR-AM + AT group (Fig. 2E and F). In addition, compared with SHR group, P-Cx43 expression was significantly increased in the treatment groups, with the highest upregulation in the SHR-AM + AT group (P<0.05; Fig. 2E and G). The P-Cx43/T-Cx43 ratio was also increased to a greater extent in the SHR-AM + AT group compared with the SHR-AM and SHR-AT groups (P<0.05; Fig. 2E and H).
Expression of T-Cx43 and P-Cx43 in myocardial tissue using immunofluorescence double labeling
Compared with the SHR group, the expression of T-Cx43 in the left ventricular myocardium was significantly decreased in other groups (P<0.05; Fig. 3A and B), whereas the expression of P-Cx43 was significantly increased (P<0.05), particularly in the SHR-AM + AT group (P<0.05; Fig. 3A and C).
Expression and distribution of T-Cx43 and P-Cx43 in the thoracic aorta using immunofluorescence double labeling
Compared with WKY group, T-Cx43 expression was increased and mainly distributed at the inner and medial membrane of the thoracic aorta. Moreover, P-Cx43 expression was decreased and mainly distributed at the medial and outer membrane in the SHR group. Compared with the SHR group, the expression of T-Cx43 was significantly decreased in the treatment groups, especially in the SHR-AM+AT group (all P<0.05; Fig. 4A and B), and the expression of P-Cx43 was significantly increased in treatment groups (P<0.05), especially in the SHR-AM+AT group (P<0.05; Fig. 4A and C).
Discussion
Hypertension is one of the most critical factors to cause left ventricular and vascular remodeling (22,23). Furthermore, ventricular remodeling is a risk factor of various severe arrhythmias, as well as sudden mortality (24). Owing to improved compliance, AM + AT have been used for treating hypertension and hyperlipidemia, and can protect vascular smooth muscle and myocardium from remodeling (25,26). Caduet is a single pill containing AM and AT, which blocks Ca2+ transmembrane influx, inhibits β-Hydroxy β-methylglutaryl-coenzyme A reductase, decreases vascular resistance and reverses ventricular remodeling (27). In addition, our previous study revealed that the expression of Cx43 was enhanced in the ventricular and thoracic aorta of SHR (15). However, the exact mechanism of AM + AT improving ventricular and thoracic aorta remodeling by regulating Cx43 phosphorylation it yet to be fully elucidated.
The present results indicated that AM + AT enhanced Cx43 phosphorylation in the left ventricular and thoracic aorta of SHR, and that AM + AT was superior to AM and AT treatment alone.
GJs serve an important role in vascular tone and blood pressure regulation (28). The GJ protein Cx43 is a sensitive pressure receptor that is closely related to the development of hypertension (29). Cardiovascular diseases have been reported to affect the expression and localization of Cx43, and dysregulated Cx43 is related to the loss of cardioprotection (30,31). Furthermore, ischemic preconditioning may reduce the incidence of arrhythmias by increasing Cx43 expression and altering GJ channel remodeling (32). In the current study, it was suggested that the upregulation of T-Cx43 and downregulation of P-Cx43 in myocardial tissue of SHR may be an adaptive response for increasing blood pressure and cardiac load. Moreover, the expression of P-Cx43 was increased and T-Cx43 was decreased after AM + AT treatment, which could contribute to enhancing GJ communication among vascular smooth muscle cells in resistant arteries of SHR group, and causing an increased response to vasoconstrictors and hypertension (33). Thus, it was concluded that AM + AT may mitigate ventricular and vascular remodeling via increased phosphorylation of Cx43.
In summary, AM + AT could improve ventricular and vascular remodeling by inhibiting T-Cx43 expression and enhancing Cx43 phosphorylation in SHR, indicating that AM + AT is superior to AM and AT alone.
Acknowledgements
Not applicable.
Funding
This research was supported by The National Key Research and Development Program of China (grant no. 2016YFD0500700), The National Natural Science Foundation of China (grant no. 81573823) and The Science and Technology Incubation Fund Project of Shaanxi Provincial People's Hospital, China (grant no. 2019YXQ-11).
Availability of data and materials
All data generated or analyzed during this study are included in this published article.
Authors' contributions
XH, JY and GC conceived and designed the experiments; XH, JY, BS, MM, HW, SW and GC performed the experiments; XH, NW and GC analyzed the data; XH, SH and NW made data interpretation and critical manuscript revisions; XH and JY wrote the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
All procedures and ethics associated with animals were reviewed and approved by Medical School of Xi'an Jiaotong University (approval no. 2018-898).
Patient consent for publication
Not applicable.
Competing interests
The authors declared that they have no competing interests.
References
Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, Damasceno A, Delles C, Gimenez-Roqueplo AP, Hering D, et al: A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: The lancet commission on hypertension. Lancet. 388:2665–2712. 2016.PubMed/NCBI View Article : Google Scholar | |
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A and Rahimi K: Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. Lancet. 387:957–967. 2016.PubMed/NCBI View Article : Google Scholar | |
Vriz O, Magne J, Jarosh J, Bossone E, Aboyans V and Palatini P: Local carotid arterial stiffness is an independent determinant of left ventricular remodeling in never-treated hypertensive patients. Blood Press. 28:23–33. 2019.PubMed/NCBI View Article : Google Scholar | |
Johnson RD and Camelliti P: Role of non-myocyte gap junctions and connexin hemichannels in cardiovascular health and disease: Novel therapeutic targets? Int J Mol Sci. 19(866)2018.PubMed/NCBI View Article : Google Scholar | |
Desai CS, Ning H and Lloyd-Jones DM: Competing cardiovascular outcomes associated with electrocardiographic left ventricular hypertrophy: The atherosclerosis risk in communities study. Heart. 98:330–334. 2012.PubMed/NCBI View Article : Google Scholar | |
Opie LH, Commerford PJ, Gersh BJ and Pfeffer MA: Controversies in ventricular remodeling. Lancet. 367:356–367. 2006.PubMed/NCBI View Article : Google Scholar | |
Camargo LL, Harvey AP, Rios FJ, Tsiropoulou S, Da Silva RNO, Cao Z, Graham D, McMaster C, Burchmore RJ, Hartley RC, et al: Vascular Nox (NADPH oxidase) compartmentalization, protein hyperoxidation, and endoplasmic reticulum stress response in hypertension. Hypertension. 72:235–246. 2018.PubMed/NCBI View Article : Google Scholar | |
Schaffer AL, Buckley NA and Pearson SA: Who benefits from fixed-dose combinations? Two-year statin adherence trajectories in initiators of combined amlodipine/atorvastatin therapy. Pharmacoepidemiol Drug Saf. 26:1465–1473. 2017.PubMed/NCBI View Article : Google Scholar | |
Chen HJ, Yao L, Chen TG, Yu M, Wang LH and Chen JZ: Atorvastatin prevents connexin43 remodeling in hypertrophied left ventricular myocardium of spontaneously hypertensive rats. Chin Med J (Engl). 120:1902–1907. 2007.PubMed/NCBI | |
Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ and Lespérance J: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian coronary atherosclerosis treatment trial. Circulation. 3:959–968. 1994.PubMed/NCBI View Article : Google Scholar | |
Salameh A: Life cycle of connexins: Regulation of connexin synthesis and degradation. Adv Cardiol. 42:57–70. 2006.PubMed/NCBI View Article : Google Scholar | |
Söhl G and Willecke K: Gap junctions and the connexin protein family. Cardiovasc Res. 62:228–232. 2004.PubMed/NCBI View Article : Google Scholar | |
Rodriguez-Sinovas A: Cx43 phosphorylation and cardioprotection. Cardiovasc Res. 83:613–614. 2009.PubMed/NCBI View Article : Google Scholar | |
Egan Benova T, Szeiffova Bacova B, Viczenczova C, Diez E, Barancik M and Tribulova N: Protection of cardiac cell-to-cell coupling attenuate myocardial remodeling and proarrhythmia induced by hypertension. Physiol Res. 65 (Suppl 1):S29–S42. 2016.PubMed/NCBI View Article : Google Scholar | |
Cheng G, Chen CY, Shou XL and Han XY: Effects of captopril on the expression of connexin 43 in thoracic aorta from spontaneous hypertensive rats. J Shaanxi Med. 44:1571–1573. 2015. | |
Martins-Marques T, Catarino S, Marques C, Matafome P, Ribeiro-Rodrigues T, Baptista R, Pereira P and Girão H: Heart ischemia results in connexin43 ubiquitination localized at the intercalated discs. Biochimie. 112:196–201. 2015.PubMed/NCBI View Article : Google Scholar | |
Martins-Marques T, Catarino S, Zuzarte M, Marques C, Matafome P, Pereira P and Girão H: Ischaemia-induced autophagy leads to degradation of gap junction protein connexin43 in cardiomyocytes. Biochem J. 467:231–245. 2015.PubMed/NCBI View Article : Google Scholar | |
Xue J, Yan X, Yang Y, Chen M, Wu L, Gou Z, Sun Z, Talabieke S, Zheng Y and Luo D: Connexin 43 dephosphorylation contributes to arrhythmias and cardiomyocyte apoptosis in ischemia/reperfusion hearts. Basic Res Cardiol. 114(40)2019.PubMed/NCBI View Article : Google Scholar | |
Hradec J, Zamorano J and Sutradhar S: Post hoc analysis of the cluster randomized usual care versus caduet investigation assessing long-term risk (CRUCIAL) trial. Curr Med Res Opin. 29:589–596. 2013.PubMed/NCBI View Article : Google Scholar | |
Lu J, Liu F, Chen F, Jin Y, Chen H, Liu D and Cui W: Amlodipine and atorvastatin improve ventricular hypertrophy and diastolic function via inhibiting TNF-α, IL-1β and NF-κB inflammatory cytokine networks in elderly spontaneously hypertensive rats. Biomed Pharmacother. 83:330–339. 2016.PubMed/NCBI View Article : Google Scholar | |
Zhang ZY, Li Y, Li R, Zhang AA, Shang B, Yu J and Xie XD: Tetrahydrobiopterin protects against radiation-induced growth inhibition in H9c2 cardiomyocytes. Chin Med J (Engl). 129:2733–2740. 2016.PubMed/NCBI View Article : Google Scholar | |
Jin Y, Jing M, Zhang L, Song S and Ma X: Internet access and hypertension management among the elderly population: A nationally representative cross-sectional survey in China. J Med Internet Res. 31(e11280)2019.PubMed/NCBI View Article : Google Scholar | |
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK and He J: Global burden of hypertension: Analysis of worldwide data. Lancet. 365:217–223. 2005.PubMed/NCBI View Article : Google Scholar | |
Delvaeye T, Vandenabeele P, Bultynck G, Leybaert L and Krysko DV: Therapeutic targeting of connexin channels: New views and challenges. Trends Mol Med. 24:1036–1053. 2018.PubMed/NCBI View Article : Google Scholar | |
Nagasawa K, Takahashi K, Matsuura N, Takatsu M, Hattori T, Watanabe S, Harada E, Niinuma K, Murohara T and Nagata K: Comparative effects of valsartan combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. Hypertens Res. 38:39–47. 2015.PubMed/NCBI View Article : Google Scholar | |
Chen Y, Chang Y, Zhang N, Guo X, Sun G and Sun Y: Atorvastatin attenuates myocardial hypertrophy in spontaneously hypertensive rats via the C/EBPβ/PGC-1α/UCP pathway. Cell Physiol Biochem. 46:1009–1018. 2018.PubMed/NCBI View Article : Google Scholar | |
Naydenov Naydenov S, Margaritov Runev N, Ivanov Manov E and Georgieva Torbova-Gigova S: Efficacy and safety of a single-pill combination of atorvastatin/amlodipine in patients with arterial hypertension and dyslipidemia. Acta Clin Croat. 57:464–472. 2018.PubMed/NCBI View Article : Google Scholar | |
Song D, Liu X, Liu R, Yang L, Zuo J and Liu W: Connexin 43 hemichannel regulates H9c2 cell proliferation by modulating intracellular ATP and [Ca2+]. Acta Biochim Biophys Sin (Shanghai). 42:472–482. 2010.PubMed/NCBI View Article : Google Scholar | |
Seki A, Nishii K and Hagiwara N: Gap junctional regulation of pressure, fluid force, and electrical fields in the epigenetics of cardiac morphogenesis and remodeling. Life Sci. 129:27–34. 2015.PubMed/NCBI View Article : Google Scholar | |
Zhai H, Dai W and Wang Y: Metoprolol protects cardiomyocytes in rabbit model of heart failure by regulating Cx43. Exp Ther Med. 15:1902–1905. 2018.PubMed/NCBI View Article : Google Scholar | |
Nao T, Ohkusa T, Hisamatsu Y, Inoue N, Matsumoto T, Yamada J, Shimizu A, Yoshiga Y, Yamagata T, Kobayashi S, et al: Comparison of expression of connexin in right atrial myocardium in patients with chronic atrial fibrillation versus those in sinus rhythm. Am J Cardiol. 91:678–683. 2003.PubMed/NCBI View Article : Google Scholar | |
Xing D, Kjølbye AL, Nielsen MS, Petersen JS, Harlow KW, Holstein-Rathlou NH and Martins JB: ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs. J Cardiovasc Electrophysiol. 14:510–520. 2003.PubMed/NCBI View Article : Google Scholar | |
Wang LJ, Ma KT, Shi WY, Wang YZ, Zhao L, Chen XY, Li XZ, Jiang XW, Zhang ZS, Li L and Si JQ: Enhance gap junction channel activity between vascular smooth muscle cells in cerebral artery of spontaneously hypertensive rats. Clin Exp Hypertens. 39:295–305. 2017.PubMed/NCBI View Article : Google Scholar |